Page last updated: 2024-10-24

potassium ion-transporting ATPase complex

Definition

Target type: cellularcomponent

Protein complex that carries out the reaction: ATP + H2O + K+(out) = ADP + phosphate + K+(in). It is a high affinity potassium uptake system. The E. coli complex consists of 4 proteins: KdpA is the potassium ion translocase, KdpB is the ATPase, and KdpC and KdpF seem to be involved in assembly and stabilization of the complex. [PMID:10608856, PMID:9858692]

The potassium ion-transporting ATPase complex, also known as the Na+/K+ ATPase or sodium-potassium pump, is a transmembrane protein complex crucial for maintaining cellular ion gradients and electrochemical potential. It is embedded in the plasma membrane, specifically the lipid bilayer, and its primary function is to transport sodium ions out of the cell and potassium ions into the cell, against their concentration gradients. This active transport process requires energy, which is supplied by the hydrolysis of ATP.

The complex is composed of two subunits: the α subunit and the β subunit. The α subunit is responsible for the catalytic activity and contains the binding sites for sodium, potassium, and ATP. It has ten transmembrane domains and is responsible for the actual ion transport. The β subunit is a glycoprotein that aids in the assembly and stability of the α subunit and may also regulate its activity. It has only one transmembrane domain and is located on the outer surface of the membrane.

The α subunit has two main conformations: E1 and E2. In the E1 conformation, the binding sites for sodium ions are accessible from the intracellular side, while in the E2 conformation, the binding sites for potassium ions are accessible from the extracellular side.

The overall process of ion transport can be summarized in the following steps:
1. Three sodium ions bind to the α subunit from the intracellular side, in the E1 conformation.
2. ATP binds to the α subunit and is hydrolyzed, releasing energy.
3. The conformational change to E2 occurs, exposing the sodium binding sites to the extracellular side and the potassium binding sites to the intracellular side.
4. Two potassium ions bind to the α subunit from the extracellular side.
5. The conformational change back to E1 occurs, exposing the potassium binding sites to the intracellular side and releasing the sodium ions to the extracellular side.
6. The potassium ions are released into the intracellular side, and the cycle repeats.

This process plays a vital role in maintaining the cell's membrane potential, which is essential for various cellular functions such as nerve impulse transmission, muscle contraction, and nutrient uptake.

The potassium ion-transporting ATPase complex is a highly regulated protein complex. Its activity can be modulated by various factors, including phosphorylation, changes in membrane potential, and interactions with other proteins. Dysfunction of this complex can lead to various diseases, including heart failure, hypertension, and neurological disorders.'
"

Proteins (3)

ProteinDefinitionTaxonomy
ATP-sensitive inward rectifier potassium channel 8An ATP-sensitive inward rectifier potassium channel 8 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q15842]Homo sapiens (human)
ATP-binding cassette sub-family C member 8An ATP-binding cassette sub-family C member 8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q09428]Homo sapiens (human)
ATP-binding cassette sub-family C member 9An ATP-binding cassette sub-family C member 9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60706]Homo sapiens (human)

Compounds (19)

CompoundDefinitionClassesRoles
diazoxidediazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.

Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
benzothiadiazine;
organochlorine compound;
sulfone
antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
glyburideglyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.

Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
monochlorobenzenes;
N-sulfonylurea
anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
pinacidilPinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)pyridines
propafenonepropafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.

Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
aromatic ketone;
secondary alcohol;
secondary amino compound
anti-arrhythmia drug
troglitazoneTroglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.chromanes;
thiazolidinone
anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidineN-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine: potassium channel openerpyridines
repaglinidepiperidines
cromakalimCromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352)
rosiglitazoneaminopyridine;
thiazolidinediones
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
mk 7675-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source
zeneca zd 6169Zeneca ZD 6169: an ATP-sensitive potassium channel opener; structure given in first source
cromakalim1-benzopyran
clamikalantclamikalant: inhibits ATP-sensitive potassium channel; structure in first source
zm226600ZM226600: an ATP-sensitive potassium channel opener; structure in first sourceanilide
way 133537
ly 465608LY 465608: a nonthiazolidinedione agonist of both PPAR-alpha and PPAR-gamma of Ligand Pharm. and Eli Lilly
bm 131246
nn 414NN 414: a hypoglycemic agent with insulin release modulating and potassium channel activating activities; structure in first source
7-chloro-3-isopropylamino-4h-1,2,4-benzothiadiazine 1,1-dioxide7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide: activates ATP-sensitive potassium channels; structure in first source